Sandbox Reserved 390: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
=='''Human topoisomerase | =='''Human topoisomerase II beta in complex with DNA and etoposide'''== | ||
<StructureSection load='3qx3' size='500' side='right' caption='Structure of the human topoisomeraseIIbcore-DNA cleavage complex stabilized by the anticancer drug etoposide. (PDB entry 3QX3)' scene=''> | <StructureSection load='3qx3' size='500' side='right' caption='Structure of the human topoisomeraseIIbcore-DNA cleavage complex stabilized by the anticancer drug etoposide. (PDB entry 3QX3)' scene=''> | ||
The purpose of this page is to explain a semisynthetic derivative of [http://en.wikipedia.org/wiki/Podophyllotoxin podophyllotoxin] [[Image:PODO.png|thumb|right|50 px|Chemical structure of podophyllotoxin]] (etoposide) that demonstrates antitumor activity by inhibiting DNA topoisomerase II, thereby inhibiting DNA re-ligation which lead to apoptosis of the cancer cell and also, to describe the mechanisms of resistance of etoposide. | The purpose of this page is to explain a semisynthetic derivative of [http://en.wikipedia.org/wiki/Podophyllotoxin podophyllotoxin] [[Image:PODO.png|thumb|right|50 px|Chemical structure of podophyllotoxin]] (etoposide) that demonstrates antitumor activity by inhibiting DNA topoisomerase II, thereby inhibiting DNA re-ligation which lead to apoptosis of the cancer cell and also, to describe the mechanisms of resistance of etoposide. | ||
<ref name=”Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011 Jul 22;333(6041):459-62.>PMID: 21778401</ref> | |||
